HYDERABAD: Pharma major Aurobindo Pharma Limited has inked a sub-license agreement with the United Nations-backed public health organisation Medicines Patent Pool (MPP) for manufacturing and supplying a generic version of Pfizer’s oral Covid-19 treatment drug nirmatrelvir to 95 countries, including India.
MPP had earlier signed a voluntary licensing agreement with Pfizer for sub-licencing nirmatrelvir and ritonavir to qualified generic drugmakers, as many as 35 of whom, including India’s Aurobindo Pharma, Torrent Pharma and Cadila Pharmaceuticals, have inked the sub-licencing pact with MPP.
